Topic:

Chutes and Ladders

Latest Headlines

Latest Headlines

Cue more drama in Teva's boardroom as its CEO announcement nears

Teva Pharmaceutical Industries appears to be on the verge of naming a replacement for former helmsman Jeremy Levin, but the  Financial Times  reports that shareholders are also pressing for a boardroom change-up that could end with a new occupant for the chairman's seat.

In a swift split, Pfizer's Schulman leaves before starting new job as vaccines head

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Pfizer head-scratcher: Schulman was toasted on Thursday, toast by Tuesday

As recently as last Thursday, Pfizer's Amy Schulman was fully expecting to move into a new and better job at Pfizer on Jan. 1. By Tuesday, she was out of a job altogether. So writes Fortune' s Patricia Sellers, who lunched with Schulman last week in New York.

Amy Schulman, tapped to lead a new Pfizer division, makes an abrupt exit

In July, Amy Schulman looked to be one of the most powerful women in Big Pharma. As part of CEO Ian Read's plan to split Pfizer's internal operations into three distinct units, he tapped Schulman to lead the company's vaccines, oncology and consumer healthcare business. Now, Schulman is out.

Ex-Merck R&D chief Kim to teach at Stanford med school

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Power struggle at Novartis? Not at all, new chairman says

Novartis Chairman Joerg Reinhardt and CEO Joe Jimenez were once in competition for the chief executive post. Jimenez won out; Reinhardt left to run Bayer Healthcare. Now, Reinhardt's back--but rather than wrest power away from Jimenez, he plans to give Jimenez more. 

GoBalto gets new CEO as founder Jae Chung steps down

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Japan's Takeda looks to outsider as it reaches for international status

Japanese drugmaker Takeda Pharmaceuticals saw an era end last year when generic versions of its top seller, diabetes drug Actos, hit the market. Now it is trying to usher in a bold new era by giving a non-Japanese executive a shot at being CEO at a particularly difficult time.

Former Roche exec Barron to head R&D at Google's Calico

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

National Human Genome Research Institute appoints director to new division

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...